International Journal of Women's Health and Reproduction Sciences

Home Aim and Scope Instructions to Authors Editorial Policies Editorial Board Authorship Agreement Form Open Access and Copyright

Jan 2020, Vol 8, Issue 1

CURRENT ISSUE ARCHIVE AHEAD OF PRINT / ACCEPTED ARTICLE MOST VIEWED ARTICLES NEWS RELATED LINKS

Advanced Search

For Author's & Reviewer's

Committee on Publication
Ethics (COPE) Flowchart

Recommendations for the Conduct

COPE: Reviewers

World Association of Medical Editors(WAME)

EQUATOR Resources : Reviewers

Poll

How do you find the scientific quality of the published articles on our web site?

Very good

Good

Fair

Bad

Very bad

Original Article
The Utility of CA125 and HE4 in Patients Suffering From Endometrial Cancer
Narges Zamani¹, Mitra Modares Gilani², Majid Mirmohammadkhani³, Sharzad Sheikhhasani², Azamsadat Mousavi², Seyedeh Reyhaneh Yousefi Sharami⁴, Setare Akhavan², Mohammad Hossein Zamani¹, Elham Saffarieh⁵
¹Department of Gynecology and Obstetrics, Imam Hospital Complex, Tehran University of Medical Sciences, Tehran, Iran ^{2³Social Determinants of Health Research Center, Semnan University of Medical Sciences, Semnan, Iran ⁴Department of Obstetrics and Gynecology, Faculty of Medicine, Kurdistan University of Medical Sciences, Sanandaj, Iran ⁵Abnormal Uterine Bl>eeding Research Center, Semnan University of Medical Sciences, Semnan, Iran}
IJWHR 2020; 8: 095-100 DOI: 10.15296/ijwhr.2020.14 Viewed : 2922 times Downloaded : 2576 times. Keywords : Endometrial cancer, Human epididymis 4, Cancer antigen 125
Full Text(PDF) \| Related Articles
Abstract

Objectives: Uterine endometrial cancer (EC) is the most common female reproductive system malignancy. There are various comments on pelvic and para-aortic lymphadenectomy during the surgical staging of EC. Several oncologists believe that total lymphadenectomy, in some cases, may lead to operative morbidity without any considerable advantage over more surveillance, especially in patients with comorbidities. The purpose of the current study was to examine the correlation between serum tumor marker levels and stage, grade, histological type, myometrial invasion, and lymph node involvement in EC. Materials and Methods: A total of 131 patients with EC participated in the present cross-sectional study. Preoperative serum CA125 and HE4 levels were evaluated 1 week before surgery. Then, the stage, grade, and lymph node involvement were recorded according to the pathological findings. After Data analysis through SPSS software, P value<0.05 was considered to be significant. Results: One hundred thirty-one patients with EC (70, 31, 15, and 15 patients in sequence with stages IA, IB, II, and III) were analyzed. The serum CA125 and HE4 levels were significantly higher in more advanced stages (over IA), (P = 0.016 and P = 0.004, respectively). Levels of both tumor markers were significantly higher in patients with lymph node involvement, and cervical and myometrial invasions. In logistic regression analysis, a significant correlation was found between HE4 level (odds ratio [OR] = 1.005, P = 0.035) and grade of disease (OR = 2.137, P = 0.005). Conclusions: HE4 and CA125 are useful for predicting high-risk patients. Sensitivity of 64% and specificity of 60% were indicated at cut-off value of 70 pmol/L for HE4 in stage IA in comparison with stages over IA. Although the ideal cut-off which is defined as higher than 80% was not obtained, such a cut-off (60%) can also be considered for preoperative evaluation of surgical staging of EC.